Clinical Trial

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.
Trial Details
NCT Number NCT07494435
Lead Sponsor Zhejiang Haichang Biotech Co., Ltd.
Conditions Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
Enrollment 230 participants
Start Date 2026-06-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-27